EUVIMEDEUVIMED entdecken
Crossref

WU-KONG28: Sunvozertinib as a Potential Chemotherapy-Sparing First-Line Option for EGFR Exon 20 Insertion-Mutant Advanced NSCLC

Runliang Ni, Yuwei Ding

Malignancy Spectrum · 2026 · 1

DOI: 10.15302/msp.2026.0020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Malignancy Spectrum, 2026. Verfasst von Runliang Ni und 1 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Ni, R., & Ding, Y. (2026). WU-KONG28: Sunvozertinib as a Potential Chemotherapy-Sparing First-Line Option for EGFR Exon 20 Insertion-Mutant Advanced NSCLC. Malignancy Spectrum, 1. https://doi.org/10.15302/msp.2026.0020

Vancouver

Ni R, Ding Y. WU-KONG28: Sunvozertinib as a Potential Chemotherapy-Sparing First-Line Option for EGFR Exon 20 Insertion-Mutant Advanced NSCLC. Malignancy Spectrum. 2026:1. doi:10.15302/msp.2026.0020

BibTeX
@article{Ni2026,
  author = {Ni, Runliang and Ding, Yuwei},
  title = {WU-KONG28: Sunvozertinib as a Potential Chemotherapy-Sparing First-Line Option for EGFR Exon 20 Insertion-Mutant Advanced NSCLC},
  journal = {Malignancy Spectrum},
  year = {2026},
  pages = {1},
  doi = {10.15302/msp.2026.0020}
}
Kostenlos starten →